PNC-27

Description:

PNC-27 is a synthetic peptide designed for cancer treatment. It has been shown to selectively target and induce apoptosis (programmed cell death) in cancer cells, while having little to no effect on normal healthy cells. The peptide works by binding to the P53 protein in cancerous cells, which is a well-known tumor suppressor. P53 plays a key role in preventing cancer formation by regulating the cell cycle and inducing cell death when cells are damaged.

PNC-27 has shown promising results in preclinical studies by exhibiting the ability to selectively kill cancer cells in a wide variety of tumors. It is considered to have oncolytic properties, meaning it could be used to target and destroy cancer cells without harming surrounding healthy tissue, unlike traditional chemotherapy.

Key Benefits and Potential Uses:

• Selective Cancer Cell Killing: PNC-27 selectively targets and induces apoptosis in cancer cells that express the P53 protein. This means it could potentially be used against cancers with active P53 pathways, such as pancreatic cancer, breast cancer, and lung cancer.

• Non-Toxic to Healthy Cells: PNC-27’s selective action ensures that healthy cells remain largely unaffected, which is a major advantage over conventional cancer therapies like chemotherapy, which often cause severe side effects by killing healthy cells along with cancer cells.

• Synergistic with Other Cancer Therapies: Preliminary studies suggest that PNC-27 may be used in combination with other cancer treatments like chemotherapy and radiation therapy to enhance overall efficacy and reduce side effects by specifically targeting cancerous cells.

• Preclinical Success: Animal studies have demonstrated that PNC-27 has a direct effect on tumor reduction, indicating it has the potential to be an effective therapy for various types of cancer.

Mechanism of Action:

PNC-27 works by binding to the P53 protein in cancer cells. The P53 protein is a tumor suppressor that is critical for regulating the cell cycle and inducing apoptosis in response to DNA damage. Many cancer cells have dysfunctional or mutated P53, but even in these cases, PNC-27 is designed to selectively interact with the mutated or unregulated P53 protein to trigger cell death.

This peptide has oncolytic properties, meaning it can specifically infect and kill cancerous cells without affecting normal cells. When the peptide binds to the P53 protein, it activates a cascade of signals within the cell that leads to cell death, thereby preventing the proliferation and growth of the cancerous tumor.

Dosage & Administration:

PNC-27 is typically administered as a subcutaneous injection after being reconstituted from its lyophilized (freeze-dried) form. The exact dosage can vary depending on the cancer type, the stage of the disease, and the treatment protocol used.

1. Reconstitution:

   • The peptide is usually reconstituted with sterile water or bacteriostatic water to form a liquid solution.

   • The recommended amount of water depends on the concentration of peptide desired. A typical amount could be 1–2 ml of water for 1 mg of PNC-27.

2. Dosage:

   • 1–5 mg per injection depending on the cancer type and treatment regimen.

   • The peptide may be used in multiple doses over several weeks, often administered on a bi-weekly or weekly basis, depending on the cancer’s response to treatment.

3. Injection Method:

   • Subcutaneous injections are most commonly used, but some protocols may require intravenous or intratumoral injections depending on the tumor location and type.

4. Treatment Cycles:

   • Treatment cycles typically involve injections for a set number of weeks, followed by periods of rest to assess the cancer’s response.